Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May-Jun;5(3):479-90.
doi: 10.4161/mabs.23995. Epub 2013 Apr 5.

Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry

Rabah Gahoual  1 , Alicia Burr  1 , Jean-Marc Busnel  2 , Lauriane Kuhn  3 , Phillipe Hammann  3 , Alain Beck  4 , Yannis-Nicolas François  1 , Emmanuelle Leize-Wagner  1
Affiliations

Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry

Rabah Gahoual et al. MAbs. 2013 May-Jun.

Abstract

Monoclonal antibodies (mAbs) are highly complex proteins that display a wide range of microheterogeneity that requires multiple analytical methods for full structure assessment and quality control. As a consequence, the characterization of mAbs on different levels is particularly product - and time - consuming. This work presents the characterization of trastuzumab sequence using sheathless capillary electrophoresis (referred as CESI) - tandem mass spectrometry (CESI-MS/MS). Using this bottom-up proteomic-like approach, CESI-MS/MS provided 100% sequence coverage for both heavy and light chain via peptide fragment fingerprinting (PFF) identification. The result was accomplished in a single shot, corresponding to the analysis of 100 fmoles of digest. The same analysis also enabled precise characterization of the post-translational hot spots of trastuzumab, used as a representative widely marketed therapeutic mAb, including the structural confirmation of the five major N-glycoforms.

Keywords: CESI-MS/MS; N-linked glycosylation; mass spectrometry; microheterogeneity; microvariant; monoclonal antibody; peptide mapping; posttranslational modifications; sheathless capillary electrophoresis.

PubMed Disclaimer

Figures

None
Figure 1. Base Peak Electropherogram corresponding to the analysis by CESI-MS/MS of trastuzumab tryptic digest. Experimental conditions: bare fused silica capillary with porous tip, total length 95 cm (30 μm i.d., 150 μm o.d.); CE voltage +20 kV; BGE 10% acetic acid; sample trastuzumab tryptic digest 2.5 mg/mL in BGE (11nL injected). MS capillary voltage: -1.3 kV, m/z range: 50–3000.
None
Figure 2. Sequence coverage obtained by CESI-MS/MS for trastuzumab HC (left-hand side) and LC (right-hand side) based on the identified peptides. Experimental conditions: see materials and methods
None
Figure 3. List of trastuzumab digested peptides identified by the CESI-MS/MS analysis. Experimental conditions: see material and methods
None
Figure 4. MS/MS spectra of peptide HT01 and HT02 illustrating the amino acid sequence retracing in the variable domain. Experimental conditions: see material and methods.
None
Figure 5. MS/MS spectra of peptide HT04 (IYPTNGYTR) (A) without modification and (B) with a deamidation on Asn55 illustrating the partial modification of the mAb and the characterization of both forms by CESI-MS/MS. Experimental conditions: see Materials and Methods.
None
Figure 6. Extracted Ion Electropherogram of m/z ratios (A) 1039.80 (HT29 + G0F), (B) 1093.78 (HT29 + G1F), (C) 972.09 (HT29 + G0), (D) 1147.82 (HT29 + G2F), (E) 991.10 (HT29 + G0). Experimental conditions: see Material and Methods.
None
Figure 7. MS/MS fragmentation spectra of (A) HT29 - G0F (precursor m/z 1039.78; charge state 3+), (B) HT29 - G1F (precursor ion 1093.80; charge state 3+), (C) HT29 - G2F (precursor ion 1147.82; charge state 3+), (D) HT29 - G0F-GlcNac (precursor ion 972.10; 3+), (E) HT29 - G0 (precursor ion 991.09; charge state 3+). Experimental conditions described in Materials and Methods section.
See this image and copyright information in PMC

References

    1. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10:345–52. doi: 10.1038/nri2747. - DOI - PubMed
    1. Reichert JM. Marketed therapeutic antibodies compendium. MAbs. 2012;4:413–5. doi: 10.4161/mabs.19931. - DOI - PMC - PubMed
    1. Ambrogelly A, Liu YH, Li H, Mengisen S, Yao B, Cannon-Carlson S, et al. Characterization of antibody variants during process development The tale of incomplete processing of N-terminal secretion peptide. MAbs. 2012;4:1–9. doi: 10.4161/mabs.21614. - DOI - PMC - PubMed
    1. Damen CWN, Chen W, Chakraborty AB, van Oosterhout M, Mazzeo JR, Gebler JC, et al. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectrom. 2009;20:2021–33. doi: 10.1016/j.jasms.2009.07.017. - DOI - PubMed
    1. Committee for medicinal products for human use (CHMP), European Medicines Agency (EMA). Guideline on development, production, characterization and specifications for monoclonal antibodies and related products 2009; EMEA/CHMP/BWP/157653/2007.

MeSH terms

LinkOut - more resources